Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Q2 net loss widens to $44.7 million; cash rises to $494.9 million

Mixed Impact 3 of 5 earnings Written later

Maze Therapeutics reported second-quarter 2026 results with a net loss of $44.7 million, or $0.76 per share, up from $33.7 million, or $0.77 per share, a year earlier. The company recognized $20.0 million in license revenue for the first half of 2026, tied to a first-quarter milestone under its Shionogi license, and ended June 30 with $494.9 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2029.

Key points

  • Q2 2026 net loss was $44.7 million ($0.76 per share), compared with $33.7 million ($0.77 per share) in Q2 2025; no license revenue was recognized in either quarter.
  • Six-month 2026 net loss was $68.9 million ($1.22 per share), compared with $66.5 million ($1.83 per share) in 2025, including $20.0 million of license revenue from a Shionogi milestone.
  • Q2 R&D expenses rose to $34.9 million from $28.1 million, and G&A expenses rose to $13.1 million from $8.4 million.
  • Cash position was $494.9 million at June 30, 2026, up from $360.0 million at December 31, 2025, following an April 2026 offering with gross proceeds of about $150 million.

The filing

CompanyMaze Therapeutics, Inc. (MAZE)
Form8-K, current report
Filed with the SECAug 11, 2026, 4:45 PM ET
Accession number0001193125-26-344878

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.